Illumina Joins WIN Consortium in Personalized Cancer Medicine
Posted: Wednesday, September 23, 2015
SAN DIEGO and VILLEJUIF, France—September 23, 2015—Illumina, Inc. (NASDAQ: ILMN), the global leader in DNA sequencing and array-based technologies, today announced it has joined the Worldwide Innovative Networking (WIN) Consortium. Founded on the recognition that greater success can be achieved through collaboration than any organization can achieve alone, the WIN Consortium is a global network of leading academic, industry, insurance and non-profit research organizations working to make personalized cancer care a reality for patients worldwide.
“We are very pleased to welcome Illumina to WIN,” said Dr. John Mendelsohn, Chairman of the WIN Consortium and the Director of the Khalifa Institute for Personalized Cancer Therapy at MD Anderson Cancer Center. “Their expertise will be invaluable as we work to accelerate the pace and reduce the cost of translating novel cancer treatments to the bedside by developing and applying, through worldwide clinical trials, the most promising advances in genomic-based cancer research.”
“The WIN Consortium is uniquely bringing together renowned institutions and cancer researchers from around the world. By working together, we will be able to generate the type of clinical utility data needed to define the value of next-generation genomic testing for oncology, as well as newer methods such as liquid biopsy,” said John Leite, Vice President of Illumina’s Oncology business. “We look forward to collaborating, with the ultimate goal of making personalized therapy a reality for cancer patients.”
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.
About the WIN Consortium
Founded in 2010, WIN is an initiative from the Institut Gustave Roussy (France) and University of Texas MD Anderson cancer center (USA). WIN is unique structurally in that it brings together organizations from academia, business and not-for-profits to focus on translating the latest advances in personalized cancer medicine into the standard of care. WIN is built on the recognition that all stakeholders in personalized cancer therapy must collaborate and share information, in order to effectively bring the latest innovations in personalized cancer care to the patient. WIN is a non-profit organization formed by 40 renowned members: Academic cancer centres (25 centers in 17 countries), companies (Blue Cross Blue Shield, Agilent Technologies, GE Healthcare, Oracle Health Services, Foundation Medicine, Takeda, AstraZeneca and Pfizer), non-profit organizations such as EORTC, CRUK and Fondation ARC. WIN organizes an annual symposium in Paris dedicated to personalized medicine. For further information, please visit www.winconsortium.org and www.winsymposium.org.
Rebecca Chambers, 858-255-5243
Jennifer Temple, 858-882-6822
Vladimir Lazar, 33 66 109 15 22
Diversity of Stakeholders - WIN Members
Studies with a global population
Sharing information to promote use of personalized, targeted cancer therapy: WIN Symposia
WIN was created to accelerate the pace and reduce the cost of translating novel cancer treatments to the bedside by developing and applying, through worldwide clinical trials and research projects, the most promising advances in genomic-based cancer research. WIN aims to initiate research projects each year in a global consortium guided by an independent scientific advisory board.
WIN now includes 37 institutional members. These stakeholders have come together from all parts of the world to address the challenge of increasing the efficacy of cancer diagnostics and therapeutics by understanding the genetics and biology of each individual’s tumor and accounting for genetic differences across diverse populations—from North and South America, Europe, Asia, and the Middle East.
Our goal is to significantly improve outcomes for patients around the globe. We aim to increase the number of patients worldwide that have access to innovative, global clinical trials in the area of genomic-based cancer therapeutics. Global diversity and inclusion of all stakeholders is WIN’s most important and differentiating asset.
Our members include leading academic, pharmaceutical, life science, not-for-profit, health, patient advocacy and IT organizations.